ATE298890T1 - Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker - Google Patents

Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker

Info

Publication number
ATE298890T1
ATE298890T1 AT00915142T AT00915142T ATE298890T1 AT E298890 T1 ATE298890 T1 AT E298890T1 AT 00915142 T AT00915142 T AT 00915142T AT 00915142 T AT00915142 T AT 00915142T AT E298890 T1 ATE298890 T1 AT E298890T1
Authority
AT
Austria
Prior art keywords
timp
metalproteinase
hibitor
tissue
matrix
Prior art date
Application number
AT00915142T
Other languages
English (en)
Inventor
Mads Holten-Andersen
Ross W Stephens
Hans Jorgen Nielsen
Ib Jarle Christensen
Nils Bruenner
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Application granted granted Critical
Publication of ATE298890T1 publication Critical patent/ATE298890T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81Protease inhibitors
    • G01N2333/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486Metalloendopeptidases (3.4.24)
    • G01N2333/96491Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494Matrix metalloproteases, e. g. 3.4.24.7
AT00915142T 1999-04-09 2000-04-10 Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker ATE298890T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199900476 1999-04-09
PCT/DK2000/000170 WO2000062070A2 (en) 1999-04-09 2000-04-10 Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker

Publications (1)

Publication Number Publication Date
ATE298890T1 true ATE298890T1 (de) 2005-07-15

Family

ID=8093987

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00915142T ATE298890T1 (de) 1999-04-09 2000-04-10 Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker

Country Status (11)

Country Link
US (6) US7108983B1 (de)
EP (2) EP1619206A3 (de)
JP (2) JP4638608B2 (de)
AT (1) ATE298890T1 (de)
AU (1) AU771309B2 (de)
CA (2) CA2366682C (de)
DE (1) DE60021068T2 (de)
ES (1) ES2244417T3 (de)
NO (1) NO329725B1 (de)
NZ (1) NZ515311A (de)
WO (1) WO2000062070A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029627A1 (en) 2002-09-26 2004-04-08 Rigshospitalet A method for detecting, screening and/or monitoring a cancer in an individual
US7374886B2 (en) * 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
US20060154245A1 (en) * 1999-04-09 2006-07-13 Rigshospitalet Method for detecting, screening and/or montoring a cancer in individual
ES2244417T3 (es) * 1999-04-09 2005-12-16 Rigshospitalet Inhibidor de tejido de metaloproteasa de matriz tipo-1 (timp-1) como un marcador de cancer.
DE60237969D1 (de) 2001-04-24 2010-11-25 Bayer Corp Menschliche antikörper gegen timp-1
AU2003226925A1 (en) * 2002-04-08 2003-10-27 Hvidovre Hospital Timp-1 as a postoperative marker for recurrent cancer
US20070117164A1 (en) * 2003-04-08 2007-05-24 Raskov Hans H Method for detection of colorectal cancer in human samples
US20080019910A1 (en) * 2004-03-30 2008-01-24 Romer Maria U Cancer Treatment and Cancer Treatment Efficacy Prediction by Blocking and Detecting Protease Inhibitors
US20100196889A1 (en) * 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
EP2126562B1 (de) * 2007-02-23 2014-12-31 Physicians Choice Laboratory Services, LLC Auf klinische eingriffe gerichtete diagnostische verfahren
WO2008138522A1 (en) * 2007-05-10 2008-11-20 Roche Diagnostics Gmbh Use of timp-1 as a marker for colorectal cancer
FR2919063B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919060B1 (fr) 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
CA2693098C (fr) * 2007-07-19 2019-06-18 Yasemin Ataman-Onal Procede de dosage de la proteine de liaison hepatique aux acides gras, de l'antigene carcino-embryonnaire, et de l'antigene carbohydrate 19-9 pour le diagnostic in vitro du cancercolorectal
FR2919064B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919061B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
WO2009091581A2 (en) * 2008-01-18 2009-07-23 Vatrix Medical, Inc. Diagnostic biomarkers for vascular aneurysm
AU2009207922B2 (en) 2008-01-23 2015-05-14 Herlev Hospital YKL-40 as a general marker for non-specific disease
WO2009149714A1 (en) * 2008-06-11 2009-12-17 Bruenner Nils Aage Selection of colorectal cancer patients for neo-adjuvant and adjuvant systemic anti-cancer treatment
FR2933773B1 (fr) 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
NZ592241A (en) 2008-09-15 2012-11-30 Herlev Hospital Ykl-40 as a marker for gastrointestinal cancers
DE102009015784A1 (de) * 2009-03-31 2010-12-02 Siemens Aktiengesellschaft In-vitro-Verfahren zur Diagnostik von Tumorerkrankungen
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
JP6182308B2 (ja) * 2012-11-13 2017-08-16 株式会社エイアンドティー 前立腺癌の鑑別診断に用いるための泳動波形データの処理方法
JP2018517892A (ja) 2015-04-10 2018-07-05 アプライド プロテオミクス,インク. 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル
AU2019251518A1 (en) * 2018-04-13 2020-09-24 Bionomics Limited Method of monitoring response to a treatment
WO2021039616A1 (ja) * 2019-08-23 2021-03-04 大日本住友製薬株式会社 併用療法及びその有効性を示すバイオマーカー

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US62070A (en) * 1867-02-12 And jeremiah kimbrough
US111359A (en) * 1871-01-31 Improvement in sewing-machines
US234776A (en) * 1880-11-23 Belt-coupling
US2086085A (en) * 1935-05-14 1937-07-06 Handley Page Ltd Aircraft control gear
US3087830A (en) * 1958-12-17 1963-04-30 Schuller Werner Hugo Wilhelm Method and apparatus for producing a dry mat sheet
US3006671A (en) * 1959-08-03 1961-10-31 Gen Precision Inc Internal staking
US6271352B1 (en) * 1985-07-12 2001-08-07 Fonden Til Fremme Af Eksperimentel Cancerforskning PAI-1 determination and use thereof
US5356817A (en) * 1988-06-09 1994-10-18 Yale University Methods for detecting the onset, progression and regression of gynecologic cancers
FR2657700A1 (fr) 1990-01-26 1991-08-02 Thomson Csf Modulateur electrooptique spatial et applications.
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
JPH0813654A (ja) 1994-07-01 1996-01-16 Sekisui House Ltd 断熱壁下地パネルの施工構造
US5569458A (en) * 1994-09-14 1996-10-29 Greenberg; Mike Nutritional formula
JPH08136548A (ja) * 1994-11-11 1996-05-31 Morinaga & Co Ltd 泌尿器癌の診断法
JP2864219B2 (ja) * 1995-02-20 1999-03-03 富士薬品工業株式会社 遊離の活性型マトリックスメタロプロテアーゼ類の分別定量法
US5643752A (en) * 1996-01-18 1997-07-01 Incyte Pharmaceuticals, Inc. Tissue inhibitor of metalloproteinases
GB9607287D0 (en) * 1996-04-09 1996-06-12 British Biotech Pharm Diagnosis method
JPH10287700A (ja) * 1997-04-10 1998-10-27 Fuji Yakuhin Kogyo Kk 活性型マトリライシン(mmp−7)に対する抗体及びそれを用いた免疫学的測定法
US5906811A (en) * 1997-06-27 1999-05-25 Thione International, Inc. Intra-oral antioxidant preparations
CN1236102A (zh) 1998-05-20 1999-11-24 徐国光 唾液癌胚抗原快速检测试剂
EP1038178A1 (de) 1998-10-08 2000-09-27 Calbiochem Novabiochem Corporation Diagnostisches verfahren für matrix-metalloproteinase 9
ES2244417T3 (es) * 1999-04-09 2005-12-16 Rigshospitalet Inhibidor de tejido de metaloproteasa de matriz tipo-1 (timp-1) como un marcador de cancer.
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
US20060154245A1 (en) * 1999-04-09 2006-07-13 Rigshospitalet Method for detecting, screening and/or montoring a cancer in individual
WO2004029627A1 (en) 2002-09-26 2004-04-08 Rigshospitalet A method for detecting, screening and/or monitoring a cancer in an individual
US6630163B1 (en) * 1999-04-22 2003-10-07 Howard Murad Method of treating dermatological disorders with fruit extracts
BR0013096A (pt) 1999-08-06 2002-05-07 Imi Internat Medical Innovatio Medição espectrofotométrica em análises imunológicos e bioquìmicos com base em cor
US7306643B2 (en) * 2000-01-10 2007-12-11 Sulzer Chemtech Ag Method for introducing additives to liquid metal, ceramic/metallic powder
MXPA03003281A (es) 2000-10-13 2004-05-21 Childrens Medical Center Deteccion enzimatica no invasiva de estados asociados con la remodelacion de tejidos.
WO2002034776A2 (en) 2000-10-26 2002-05-02 K.U.Leuven Research And Development Epitopes of pai-1
JP2004524010A (ja) 2000-11-30 2004-08-12 モルキューラー スキンケア リミテッド 疾患の診断および処置
DE60237969D1 (de) 2001-04-24 2010-11-25 Bayer Corp Menschliche antikörper gegen timp-1
US6815181B2 (en) 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
AU2002365066A1 (en) * 2001-07-18 2003-07-09 American Red Cross Mutant proteinase inhibitors and uses thereof
KR100475642B1 (ko) 2001-12-29 2005-03-10 한국생명공학연구원 암 발생 및 전이에 관여하는 단백질의 당쇄 변화를측정하여 암을 진단하는 방법 및 이를 이용한 진단킷트
AU2003226925A1 (en) 2002-04-08 2003-10-27 Hvidovre Hospital Timp-1 as a postoperative marker for recurrent cancer
EP1382969A1 (de) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnose und Behandlung der Invasion von Krebszellen
US20040157278A1 (en) 2002-12-13 2004-08-12 Bayer Corporation Detection methods using TIMP 1
CN105316405A (zh) 2003-07-17 2016-02-10 环太平洋生物技术有限公司 用于胃癌检测的标记物
US20080019910A1 (en) * 2004-03-30 2008-01-24 Romer Maria U Cancer Treatment and Cancer Treatment Efficacy Prediction by Blocking and Detecting Protease Inhibitors

Also Published As

Publication number Publication date
EP1171771A2 (de) 2002-01-16
CA2366682A1 (en) 2000-10-19
US7807379B2 (en) 2010-10-05
WO2000062070A2 (en) 2000-10-19
AU771309B2 (en) 2004-03-18
EP1619206A3 (de) 2006-02-15
US20110060529A1 (en) 2011-03-10
JP2002541481A (ja) 2002-12-03
DE60021068D1 (de) 2005-08-04
WO2000062070A3 (en) 2001-01-25
CA2366682C (en) 2009-06-23
CA2652131A1 (en) 2000-10-19
NO329725B1 (no) 2010-12-06
US20070020707A1 (en) 2007-01-25
NO20014869D0 (no) 2001-10-05
JP2010266455A (ja) 2010-11-25
EP1619206A2 (de) 2006-01-25
ES2244417T3 (es) 2005-12-16
AU3655600A (en) 2000-11-14
US20090035794A1 (en) 2009-02-05
EP1171771B1 (de) 2005-06-29
NO20014869L (no) 2001-12-04
DE60021068T2 (de) 2006-05-18
US20110294148A1 (en) 2011-12-01
US20080261246A1 (en) 2008-10-23
JP4638608B2 (ja) 2011-02-23
NZ515311A (en) 2002-11-26
US7108983B1 (en) 2006-09-19

Similar Documents

Publication Publication Date Title
ATE298890T1 (de) Gewebeinhibitor der matrix-metalproteinase typ 1 (timp-1) als krebsmarker
ATE283485T1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
DE60042695D1 (de) Verfahren für den nachweis von erkrankungen
FI904534A0 (fi) Foerfarande och anordning foer amperometrisk diagnosanalys.
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
ES2107465T3 (es) Ensayo antioxidante.
ATE412749T1 (de) Chemisch modifizierter gewebeinhibitor für metalloproteasen type 3 (timp-3)
EP1099102A4 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
ATE532070T1 (de) Entzündungsmarker zum nachweis und zur prävention von diabetes mellitus
DE60123797D1 (de) Ionenkanal-testverfahren
AU2003259222A1 (en) Method of diagnosing alzheimer's disease
PT1058738E (pt) Metodo de seleccao por via de polarizacao de fluorescencia
BR0012921A (pt) Compostos calcilìticos
DE50109698D1 (de) N-heteroarylmethyl-m-phenylendiamin-derivate enthaltende färbemittel für keratinfasern sowie neue n-heteroarylmethyl-m-phenylendiamin-derivate
WO2001063293A3 (en) Diagnosis and treatment of schizophrenia
WO2001090408A3 (fr) Detection et caracterisation de l'activite de proteines impliquees dans la reparation de lesions de l'adn
ATE374370T1 (de) Verfahren zur diagnose von endometriose
DK0760482T3 (da) Metode til bedømmelse af udryddelse af H. Pylori på basis af graden af ændringer i pepsinogen I/II-forholdet
ATE420361T1 (de) Marker für therapie mit antidepressiva und damit in zusammenhang stehende verfahren
ATE481498T1 (de) Verfahren zur messung von neprilysinaktivität
ATE195151T1 (de) Verfahren zur bewertung von substanzen zum steigen bzw. zur modifizierung der apc-aktivität
DE69003323D1 (de) Flüssige zubereitung für intraokulare perfusion.
DE60022487D1 (de) In vivo färbemittel und verwendungsmethoden zur identifizierung von dysplastischem gewebe
ATE229183T1 (de) Verfahren zur reihenuntersuchung auf prostatakrebs durch messung des apolipoprotein-d- spiegels in körperflüssigkeiten
DE60000965D1 (de) Pseudopeptid, verfahren zur herstellung, reagenz und verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties